Prognostic value of platelet to lymphocyte ratio in patients with cervical cancer: an updated systematic review and meta-analysis

Table 2 Pooled HRs for OS, DFS and PFS in subgroup analyses

Subgroup	OS(Baseline)				DFS(Baseline)				PFS(Baseline)
Subgroup	Study	HR [95%CI]	P value	I²	Study	HR [95%CI]	P value	I²	Study	HR [95%CI]	P value	I²
*Total*	28	1.77 [1.43, 2.19]	<0.00001	87%	5	1.57 [1.12–2.18]	0.008	37%	13	1.69 [1.26, 2.27]	0.0004	77%
Treatment
Surgery	5	1.97 [1.14, 3.38]	0.01	51%	2	1.34 [0.59, 3.07]	0.49	69%	2	2.74 [1.52, 4.94]	0.0008	0
Radiochemotherapy	14	1.66 [1.29, 2.14]	<0.0001	78%	2	1.87 [1.00, 3.50]	0.05	45%	8	1.43 [1.06, 1.93]	0.02	74%
Surgery + Radiochemotherapy	1	1.54 [1.03, 2.32]	0.04	NA	1	1.59 [1.06, 2.39]	0.03	NA	NA	NA	NA	NA
Mean/median age
≥ 50y	16	1.60 [1.22, 2.09]	0.0006	80%	2	1.87 [1.00, 3.50]	0.05	45%	7	1.55 [1.12, 2.16]	0.008	47%
< 50y	9	1.99 [1.58, 2.52]	<0.00001	0	3	1.43 [0.92, 2.22]	0.11	47%	4	2.36 [1.51, 3.67]	0.0001	0
Region
Asia	22	1.71 [1.43, 2.06]	<0.00001	36%	4	1.62 [1.07, 2.46]	0.02	52%	12	1.61 [1.21, 2.15]	0.001	70%
America	2	1.95 [1.69, 2.25]	<0.00001	0	NA	NA	NA	NA	1	2.30 [1.51, 3.51]	0.0001	NA
Europe	4	1.80 [0.92, 3.53]	0.08	93%	1	1.36 [0.71, 2.62]	0.36	NA	NA	NA	NA	NA
PLR cut-off
≥ 150	9	1.66 [1.28, 2.15]	0.0001	47%	1	1.36 [0.71, 2.62]	0.36	NA	11	1.74 [1.25, 2.42]	0.001	79%
< 150	18	1.82 [1.39, 2.38]	<0.0001	84%	3	1.43 [0.92, 2.22]	0.11	47%	2	1.60 [0.55, 4.64]	0.39	72%

ISSN: 1477-7819